Vincerx Pharma, Inc. (VINC): Price and Financial Metrics
VINC Price/Volume Stats
| Current price | $0.85 | 52-week high | $9.37 |
| Prev. close | $0.90 | 52-week low | $0.61 |
| Day low | $0.83 | Volume | 350,626 |
| Day high | $0.91 | Avg. volume | 1,293,254 |
| 50-day MA | $4.08 | Dividend yield | N/A |
| 200-day MA | $1.74 | Market Cap | 18.20M |
VINC Stock Price Chart Interactive Chart >
Vincerx Pharma, Inc. (VINC) Company Bio
Vincerx Pharma, Inc. operates as a clinical-stage life sciences company. The Company focuses on developing VIP152 inhibits PTEFb phosphorylation of RNA polymerase II (RNAPII), thereby preventing transcription elongation and blocking expression of genes that drive cancer. Vincerx Pharma serves customers worldwide.
Latest VINC News From Around the Web
Below are the latest news stories about VINCERX PHARMA INC that investors may wish to consider to help them evaluate VINC as an investment opportunity.
15 Best Falling Stocks To Buy NowIn this article, we will take a detailed look at the 15 Best Falling Stocks To Buy Now. For a quick overview of such stocks, read our article 5 Best Falling Stocks To Buy Now. The Wall Street is headed to end 2023 on a strongly positive note as the Fed’s indication of coming rate cuts have infused a […] |
Vincerx Pharma Presents Preclinical VIP943 and VIP924 Posters at ASH 2023Poster on VIP943, a novel CD123-targeted antibody-drug conjugate (ADC) from our VersAptx™ platform, showcases selectivity, activity, and safety of VIP943 Poster on VIP924, a first-in-class CXCR5-targeted ADC from our VersAptx platform, shows superior activity and safety compared with commercially available B-cell targeted ADCs PALO ALTO, Calif., Dec. 10, 2023 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC)(“Vincerx”), a biopharmaceutical company aspiring to address the unmet medical need |
Vincerx Pharma Reports Third Quarter 2023 Financial Results and Provides Corporate UpdatePhase 1 dose escalation for VIP943 - first antibody-drug conjugate (ADC) from VersAptx™, versatile and adaptable, next-generation bioconjugation platform - moves quickly into 2nd cohort Phase 1 dose escalation for VIP236 - first-in-class small molecule-drug conjugate (SMDC) for treatment of solid tumors - progressing well with optimized dosing schedule Phase 1 dose escalation combination study for enitociclib in collaboration with NIH - partial response in first patient dosed in second cohort Ca |
Vincerx Pharma To Present Three Posters at ASH 2023 in DecemberVIP943 poster supports selectivity and safety of lead CD123 ADC, VIP943, currently in Phase 1 VIP924 poster shows this novel CXCR5-ADC compares favorably with other ADCs in clinical development Enitociclib poster expands potential clinical indications PALO ALTO, Calif., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC)(“Vincerx”), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, today annou |
New to The Street Airs Televised Corporate Interviews Episodes 521 and 522 as Sponsored Programming on Bloomberg TV and The Fox Business NetworkAirings start on Bloomberg TV on Saturday, October 14, 2023, at 6:30 PM ET, followed by the FOX Business Network show on Sunday, October 15, 2023, at 3:30 PM ET New to The Street Airs Televised Corporate Interviews Episodes 521 and 522 as Sponsored Programming on Bloomberg TV and The Fox Business Network Episodes 521/522: 1).Vincerx Pharma, Inc. (NASDAQ: VINC) ($VINC) 2). Surf Air Mobility, Inc. (NYSE: SRFM) ($SRFM) 3). PetVivo Holdings, Inc. (NASDAQ: PETV) (NASDAQ: PETVW) ($PETV) 4). Mangoceuti |
VINC Price Returns
| 1-mo | -87.31% |
| 3-mo | -20.56% |
| 6-mo | -13.71% |
| 1-year | -15.00% |
| 3-year | -94.83% |
| 5-year | N/A |
| YTD | -27.97% |
| 2023 | 15.69% |
| 2022 | -89.99% |
| 2021 | -51.27% |
| 2020 | N/A |
| 2019 | N/A |
Loading social stream, please wait...